Skip to content
Head to head

Bio-Techne vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: TECH · VRTX

Updated 6 minutes ago

1-year performance, rebased to 100

TECH +24.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals trades cheapest on trailing earnings; Vertex Pharmaceuticals earns the most per share.
TECHVRTX
Snapshot
Sector--Biotechnology
Last price72.67515.02
Change today-0.04%-1.08%
1-year return+24.4%+22.0%
Market cap$11.42B$130.58B
52-week range43.02 – 72.86412.27 – 568.67
Valuation
P/E (TTM)66.0633.14
P/E percentile, own 5-yr range57th99th
P/B5.276.25
Dividend yield0.44%0.00%
Profitability & growth
EPS (TTM)1.1615.32
Net profit (TTM)$182.23M$3.88B
Revenue (TTM)$1.23B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+4.6%+11.8%
Gross margin65.8%85.5%
Operating margin21.3%33.1%
Net margin14.0%30.7%
Free cash flow (TTM)$308.20M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership108.5%96.8%
Insider activity (12mo)27 buy / 23 sell28 buy / 22 sell
Short interest (% of float)4.9%1.9%
Analyst consensus50% hold / 50% sell (2)95% buy / 5% hold (21)
Analyst price target$73 (+0%)$624 (+21%)
StockVane view
StockVane Quant RatingC (72)C (68)
Company
Employees3,0006,400
Founded19761989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.